摘要
目的分析中性粒细胞与淋巴细胞比(NLR)、前列腺特异性抗原(PSA)对前列腺癌发生去势抵抗性前列腺癌(CRPC)的预测价值。方法回顾性分析152例前列腺癌患者临床资料,分析NLR、PSA与前列腺癌的临床病理特征的关系,前列腺癌患者发生CRPC的独立危险因素采用多元Logistic回归分析。结果152例前列腺癌患者中,NLR升高80例,降低72例,PSA升高82例,降低70例,NLR与前列腺癌患者的肿瘤分期、骨转移情况、Gleason评分及改良格拉斯哥预后评分(mGPS)等可能有关(P<0.05);PSA与前列腺癌患者的肿瘤分期、Gleason评分及mGPS评分等可能有关(P<0.05)。Logistic回归分析结果显示,肿瘤分期为Ⅲ~Ⅳ期、有骨转移、Gleason评分≥8分、mGPS评分为1~2分、PSA≥100.0 ng/ml及NLR≥2.3是导致前列腺癌患者发生CRPC的独立危险因素(P<0.05)。结论PSA、NLR与前列腺癌患者的肿瘤分期、Gleason评分及mGPS评分等临床特征密切相关,PSA、NLR升高是导致CRPC发生的独立危险因素,可作为预测前列腺癌CRPC发生的重要指标。
Objective To analyze the predictive value of neutrophil to lymphocyte ratio(NLR)and prostate specific antigen(PSA)for the occurrence of castrate-resistant prostate cancer(CRPC)in patients with prostate cancer.Method Clinical data of 152 patients with prostate cancer were retrospectively analyzed,and relationship of NLR and PSA with clinical pathological characteristics of prostate cancer was analyzed.Multiple Logistic regression was used to analyze the independent risk factors for the occurrence of CRPC.Result NLR increased in 80 cases and decreased in 72 cases,PSA increased in 82 cases and decreased in 70 cases.NLR was associated with tumor stage,bone metastasis,Gleason score and modified Glasgow prognostic score(mGPS)of patients with prostate cancer(P<0.05).PSA was associated with the tumor stage,Gleason score and mGPS score of patients with prostate cancer(P<0.05).Logistic regression model showed tumor stage Ⅲ-Ⅳ,bone metastasis,Gleason score≥8,mGPS score in 1-2 and increase of PSA≥100.0 ng/ml and NLR≥2.3 were independent risk factors for CRPC in patients with prostate cancer(P<0.05).Conclusion PSA and NLR are closely related to the clinical characteristics(tumor stage,Gleason score and mGPS score)of patients with prostate cancer.Increases of PSA and NLR are independent risk factors for the occurrence of CRPC,which can be used as important indicators for prediction of CRPC in prostate cancer.
作者
宋益挺
杜永辉
赵刚刚
SONG Yiting;DU Yonghui;ZHAO Ganggang(Department of Urology,the First Affiliated Hospital of Xi’an Medical University,Xi’an 710077,Shaanxi,China;Department of Urology,the Second Affiliated Hospital of Xi’an Medical University,Xi’an 710038,Shaanxi,China)
出处
《癌症进展》
2020年第20期2126-2129,共4页
Oncology Progress
